Prosecution Insights
Last updated: November 20, 2026
Application No. 17/928,894

THERAPEUTIC DRUG FOR DISEASE CAUSED BY INTESTINAL IMMUNE DISORDER

Non-Final OA §103§112
Filed
Nov 30, 2022
Priority
Jun 01, 2020 — JP 2020-095241 +1 more
Examiner
WELLS, LAUREN QUINLAN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Keio University
OA Round
3 (Non-Final)
49%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
129 granted / 261 resolved
-10.6% vs TC avg
Strong +60% interview lift
Without
With
+59.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
89 currently pending
Career history
354
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
36.0%
-4.0% vs TC avg
§102
15.2%
-24.8% vs TC avg
§112
28.4%
-11.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 261 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 07/09/2026 has been entered. The amendment filed 07/09/2026, amended claim 12 and cancelled claims 13-15 and 17-18. Claims 1-12, 16 and 19-20 are pending. Priority This application claims the following priority: PNG media_image1.png 89 656 media_image1.png Greyscale Election/Restrictions Applicant elected Group III, a method of treating a disease, and the species a) inflammatory bowel disease as the disease, and b) administering an agonist or an antagonist of a muscarinic acetylcholine receptor to a subject to be treated, as the type of regulating the amount of peripheral regulatory T cells in the gut, in the reply filed on 08/04/2025. Claims 1-11 and 20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention and species, there being no allowable generic or linking claim. Claims 12, 16, and 19 are examined on the merits herein. REJECTIONS WITHDRAWN The status for each rejection and/or objection in the previous Office Action is set out below. 35 USC § 102 Applicant’s amendment to independent claim 12 that limits the disease to an inflammatory bowel disease and adds a “determining” step, is sufficient to overcome the previous prior art rejections. REJECTIONS-NEW The rejections are new. However, US2017/0246267 to Wang continues to be relied upon as a prior art reference. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 16 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 16 is indefinite because it depends from a deleted base claim. If the base claim has been canceled, a claim which is directly or indirectly dependent thereon should be rejected as incomplete. MPEP 608.01(n). For the purpose of applying prior art, claim 16 is interpreted as depending on claim 12. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 12, 16 and 19 are rejected under 35 U.S.C. 103 as being unpatentable over US 2017/0246267 to Wang (published 2017, PTO-892 of 10/06/2025) in view of Pedros (Disrupted regulatory T cell homeostasis in inflammatory bowel diseases, published 2016, PTO-892). Wang teaches a method for stimulating regeneration of the colon or stomach in a subject with inflammatory bowel disease by administering a cholinergic agonist, wherein the cholinergic agonist is pilocarpine or bethanechol (pgs. 45-46, claims 5, 23, 24). Regarding claim 12, Wang differs in that it does not teach determining pTreg inducing activity. Pedros teaches that regulatory T cells (Tregs) play a pivotal role in ensuring gut health. Tregs are able to prevent excessive inflammation, which can lead to the rupture of intestinal homeostasis observed in inflammatory bowel diseases (IBDs) (abstract). Pedros teaches that Tregs can be divided into two main subsets, tTregs and pTregs, wherein pTregs are peripherally induced Tregs and tTregs are thymus derived Tregs (pg. 976, Col. 1). Pedros teaches that pTregs are derived from conventional Tcells in the gut (pg. 976, Col. 1). The composition of the microbiota is crucial for Treg accumulation. “. . .the intestinal bacteria promote tolerance by producing molecules that improve Treg mediated immunosuppression, thus allowing symbiosis between the intestinal flora and the host. . .pTregs. . .prevent immune responses against commensal and dietary antigens. . .Indeed a large proportion of colonic Tregs are specific for bacterial antigens, suggesting that pTregs compose a major proportion of the gut Tregs. . .both pTregs and tTregs. . .contribute to the maintenance of intestinal homeostasis” (pgs. 976-977, “Thymic and peripheral regulatory T cell subpopulations”). Pedros teaches Tregs as a key immunosuppressive population that is critically involved in the maintenance of the intestinal homeostasis (pg. 975, Col. 2). “Importantly, from a clinical perspective, Tregs can also cure established colitis. Thus, in contrast to the in vitro reductionist Treg/Teff coculture model, this mouse model of intestinal inflammation is a potent tool to dissect the Treg immunosuppressive mechanisms in vivo” (pg. 981, Col. 1). Pedros teaches that “Numerous studies investigating Tregs in human IBDs show that patients exhibit decreased Treg numbers in the blood and increased Treg numbers in the inflamed intestinal mucosa compared to the uninflamed tissues. The circulating Treg percentages inversely correlate with disease activity, and a concomitant increase in the mucosal Treg numbers is associated with a reduction of the circulating Treg population in active disease” (pg. 984, Col. 1). It would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to add to the methods of Wang, a step of determining pTreg inducing activity, as taught by Pedros, to arrive at instant claim 12, One of ordinary skill in the art would have been motivated to make such an addition, with a reasonable expectation of success, because: -Wang teaches a method of treating inflammatory bowel disease, -Pedros teaches Tregs as a key immunosuppressive population that is critically involved in the maintenance of the intestinal homeostasis, - Pedros teaches that regulatory T cells (Tregs) play a pivotal role in ensuring gut health, wherein Tregs are able to prevent excessive inflammation, which can lead to the rupture of intestinal homeostasis observed in inflammatory bowel diseases, -Pedros teaches pTregs as composing a major proportion of the gut Tregs, contributing to the maintenance of intestinal homeostasis. As such, an ordinary skilled artisan would have been motivated to add such a step to predictably arrive at a method that determines the intestinal homeostasis status of a patient, and which monitors the effectiveness of the method of treatment by monitoring the intestinal homeostasis. Regarding claim 16, Wang teaches pilocarpine and bethanechol. Regarding claim 19, Wang teaches that “subject” includes all members of the animal kingdom including, but not limited to, mammal, animals, and humans ([0089]). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAUREN WELLS whose telephone number is (571)272-7316. The examiner can normally be reached M-F 7:00-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James (Jim) Alstrum-Acevedo can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAUREN WELLS/Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Nov 30, 2022
Application Filed
Oct 06, 2025
Non-Final Rejection mailed — §103, §112
Feb 02, 2026
Response Filed
Apr 09, 2026
Final Rejection mailed — §103, §112
Jul 09, 2026
Request for Continued Examination
Jul 12, 2026
Response after Non-Final Action
Nov 04, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799116
CYCLIC FORMYL AND CYCLIC KETONE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE
5y 0m to grant Granted Nov 17, 2026
Patent 12797365
COMPOSITIONS AND METHODS FOR MODULATING TRP CHANNEL ACTIVITY
4y 0m to grant Granted Nov 17, 2026
Patent 12797400
NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASES
4y 0m to grant Granted Nov 17, 2026
Patent 12788768
COMPOSITION COMPRISING CANNABINOIDS, AND/OR TERPENS, AND METHODS OF USING SAME
3y 8m to grant Granted Nov 10, 2026
Patent 12788737
SUBSTANCES FOR TREATMENT OF HYPERURICAEMIA
3y 6m to grant Granted Nov 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
49%
Grant Probability
99%
With Interview (+59.5%)
3y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 261 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month